Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant
Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant
辉瑞/BioNTech更新的基于奥密克戎的新冠肺炎疫苗显示对变体的更好反应
- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response.
- The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant.
- Also Read: Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months.
- A version of the shot that contained both the redesigned vaccine and their original vaccine elicited a 9.1 and 10.9-fold increase.
- The results were from a trial of 1,234 people aged 56 or older. The shots were well-tolerated in participants, the companies said.
- Early laboratory studies suggest that both Omicron-modified candidates neutralize the omicron BA.4 and BA.5 subvariants, though to a lesser extent than they do for BA.1, with titers approximately 3-fold lower.
- The companies will continue to collect additional study data on Omicron BA.4/BA.5 over the coming weeks.
- Price Action: PFE shares are down 0.02% at $51.60, and BNTX stock is up 3.07% at $138.15 during the premarket session on the last check Monday.
- Image by x3 from Pixabay
- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response.
- The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant.
- Also Read: Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months.
- A version of the shot that contained both the redesigned vaccine and their original vaccine elicited a 9.1 and 10.9-fold increase.
- The results were from a trial of 1,234 people aged 56 or older. The shots were well-tolerated in participants, the companies said.
- Early laboratory studies suggest that both Omicron-modified candidates neutralize the omicron BA.4 and BA.5 subvariants, though to a lesser extent than they do for BA.1, with titers approximately 3-fold lower.
- The companies will continue to collect additional study data on Omicron BA.4/BA.5 over the coming weeks.
- Price Action: PFE shares are down 0.02% at $51.60, and BNTX stock is up 3.07% at $138.15 during the premarket session on the last check Monday.
- Image by x3 from Pixabay
- 辉瑞(纽约证券交易所股票代码：PFE)和BioNTech SE纳斯达克(Sequoia Capital：BNTX)表示，针对奥密克戎冠状病毒变异株的改良疫苗产生了更高的免疫应答。
- 两家公司表示，仅针对BA.1奥密克戎亚型的30微克和60微克剂量的疫苗，针对该亚型的中和几何滴度分别增加13.5倍和19.6倍。
- 另请阅读： 辉瑞-生物技术新冠肺炎疫苗获得FDA紧急使用许可，适用于年仅6个月的儿童.
- 同时包含重新设计的疫苗和原始疫苗的疫苗版本获得了9.1倍和10.9倍的增长。
- 这一结果来自对1234名年龄在56岁或以上的人的试验。两家公司表示，参与者对注射的耐受性很好。
- 早期的实验室研究表明，这两种奥密克戎修饰的候选疫苗都能中和奥密克戎BA.4和BA.5亚型，尽管程度比BA.1小，效价大约低3倍。
- 未来几周，两家公司将继续收集有关奥密克戎BA.4/BA.5的更多研究数据。
- 价格行动：周一收盘前，PFE股价下跌0.02%，至51.6美元，BNTX股价上涨3.07%，至138.15美元。
- 图片来自Pixabay的X3
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧
点击这里分享给好友
暂无评论，快来抢沙发吧！